title: Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
abstract: BACKGROUND
  The treatment of glioblastomas (GBMs) has changed significantly since 2005. However, the extent to which this change has improved overall survival (OS) of patients treated outside clinical trials remains to be determined.
  
  
  METHODS
  We compared the patterns of care and OS of all GBM patients diagnosed in 2004 (n=105) and in 2008 (n=130) in our center.
  
  
  RESULTS
  Younger patients (aged<70 years) diagnosed in 2008 received temozolomide radiochemotherapy as the initial treatment and bevacizumab at recurrence more frequently than those diagnosed in 2004 (69% vs 26% P<10(-4) and 41% vs 3%, P<10(-4), respectively). Elderly patients (aged≥70 years) diagnosed in 2008 received an oncological treatment (radiotherapy and/or chemotherapy) more frequently than those diagnosed in 2004 (67% vs 38%, P=0.006). The patients diagnosed in 2008 had longer OS than those diagnosed in 2004 (10.5 months vs 5.3 months, P=0.001). This finding was true for both younger and elderly patients (15.3 months vs 8.9 months, P=0.02 and 6.4 months vs 3.2 months, P=0.0002, respectively) and when considering only IDH1 wild-type patients (8.9 months vs 5.3 months, P=0.004).
  
  
  CONCLUSIONS
  In our center, the change in the patterns of care for GBMs between 2004 and 2008 has been associated with a significant improvement in OS.
authors.affiliation: Service de neuro-oncologie, hôpital neurologique Pierre-Wertheimer, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France.
authors.forename: N
authors.initials: N
authors.lastname: Badaoui
authors.affiliation: Université de Lyon, Claude-Bernard Lyon 1, 43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex, France; Lyon Neuroscience Research Center INSERM U1028/CNRS UMR 5292, centre de recherche en neurosciences de Lyon, équipe neuro-oncologie et neuro-inflammation, faculté Laënnec, 8, rue G.-Paradin, 69008, Lyon, France; Service de neuropathologie, hôpital neurologique Pierre-Wertheimer, groupe hospitalier Est, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France.
authors.forename: D
authors.initials: D
authors.lastname: Meyronet
authors.affiliation: Service de neuro-oncologie, hôpital neurologique Pierre-Wertheimer, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France.
authors.forename: S
authors.initials: S
authors.lastname: Cartalat-Carel
authors.affiliation: Service de neurochirurgie D, hôpital neurologique Pierre-Wertheimer, groupe hospitalier Est, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France.
authors.forename: J
authors.initials: J
authors.lastname: Guyotat
authors.affiliation: Université de Lyon, Claude-Bernard Lyon 1, 43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex, France; Lyon Neuroscience Research Center INSERM U1028/CNRS UMR 5292, centre de recherche en neurosciences de Lyon, équipe neuro-oncologie et neuro-inflammation, faculté Laënnec, 8, rue G.-Paradin, 69008, Lyon, France; Service de neurochirurgie A, hôpital neurologique Pierre-Wertheimer, groupe hospitalier Est, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France.
authors.forename: E
authors.initials: E
authors.lastname: Jouanneau
authors.affiliation: Service de radiothérapie oncologie, centre hospitalier Lyon Sud, Hospices Civils de Lyon, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
authors.forename: A
authors.initials: A
authors.lastname: d'Hombres
authors.affiliation: Centre Léon-Bérard, 28, Promenade-Léa et Napoléon-Bullukian, 69008 Lyon, France.
authors.forename: M P
authors.initials: MP
authors.lastname: Sunyach
authors.affiliation: Université de Lyon, Claude-Bernard Lyon 1, 43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex, France; Lyon Neuroscience Research Center INSERM U1028/CNRS UMR 5292, centre de recherche en neurosciences de Lyon, équipe neuro-oncologie et neuro-inflammation, faculté Laënnec, 8, rue G.-Paradin, 69008, Lyon, France; Service de neuropathologie, hôpital neurologique Pierre-Wertheimer, groupe hospitalier Est, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Jouvet
authors.affiliation: Service de neuro-radiologie, hôpital neurologique Pierre-Wertheimer, groupe hospitalier Est, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France.
authors.forename: G
authors.initials: G
authors.lastname: Louis-Tisserand
authors.affiliation: Service de neuro-oncologie, hôpital neurologique Pierre-Wertheimer, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Archinet
authors.affiliation: Centre Léon-Bérard, 28, Promenade-Léa et Napoléon-Bullukian, 69008 Lyon, France.
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.affiliation: Service de neurochirurgie, centre Gui-de-Chauliac, CHU de Montpellier, 2, avenue Emile-Bertin-Sans, 34295 Montpellier, France.
authors.forename: L
authors.initials: L
authors.lastname: Bauchet
authors.affiliation: Service de neuro-oncologie, hôpital neurologique Pierre-Wertheimer, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France; Université de Lyon, Claude-Bernard Lyon 1, 43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex, France; Lyon Neuroscience Research Center INSERM U1028/CNRS UMR 5292, centre de recherche en neurosciences de Lyon, équipe neuro-oncologie et neuro-inflammation, faculté Laënnec, 8, rue G.-Paradin, 69008, Lyon, France.
authors.forename: J
authors.initials: J
authors.lastname: Honnorat
authors.affiliation: Service de neuro-oncologie, hôpital neurologique Pierre-Wertheimer, Hospices Civils de Lyon, 59, boulevard Pinel 69394 Lyon cedex, France; Université de Lyon, Claude-Bernard Lyon 1, 43, boulevard du 11 novembre 1918, 69622 Villeurbanne cedex, France; Lyon Neuroscience Research Center INSERM U1028/CNRS UMR 5292, centre de recherche en neurosciences de Lyon, équipe neuro-oncologie et neuro-inflammation, faculté Laënnec, 8, rue G.-Paradin, 69008, Lyon, France. Electronic address: francois.ducray@chu-lyon.fr.
authors.forename: F
authors.initials: F
authors.lastname: Ducray
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D059248:Chemoradiotherapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019468:Disease Management; D005260:Female; D005602:France / Q000453:epidemiology; D005909:Glioblastoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D010166:Palliative Care; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide
keywords: Bevacizumab; Bévacizumab; Epidemiology; Glioblastoma; Glioblastome; Patterns of care; Temozolomide; Traitement; Témozolomide; Épidemiologie